Art

J-GLOBAL ID：201702225927499307   Reference number：17A0816512

Demeanor of rivaroxaban in activated/inactivated FXa

活性化/不活性化FXaにおけるリバロキサバンの挙動

Author (10)： Seki Kaname (Department of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan) ,  Mizuno Yosuke (Division of Functional Genomics & Systems Medicine, Saitama Medical University Research Center for Genomic Medicine, Saitama, Japan) ,  Sakashita Toku (Department of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan) ,  Nakano Shintaro (Department of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan) ,  Tanno Jun (Department of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan) ,  Okazaki Yasushi (Division of Functional Genomics & Systems Medicine, Saitama Medical University Research Center for Genomic Medicine, Saitama, Japan) ,  Muramatsu Toshihiro (Department of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan) ,  Nishimura Shigeyuki (Department of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan) ,  Senbonmatsu Takaaki (Department of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan) ,  Senbonmatsu Takaaki (Research Administration Center, Saitama Medical University, Saitama, Japan)
Material： Journal of Pharmacological Sciences (Web)  (J Pharmacol Sci (Web))
Volume： 133  Issue： 3  Page： 156-161  Publication year： 2017 
JST Material Number： U0667A  ISSN： 1347-8613  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Thesaurus term： factor X ,...
Semi thesaurus term： *factor Xa inhibitor

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0816512&from=J-GLOBAL&jstjournalNo=U0667A") }}

Author keywords (5)： Activated factor X ,  Anticoagulant ,  Inflammation ,  Rivaroxaban ,  Gene modulation

JST classification (1)： Basic research of drugs acting on blood and body fluid  (GW14010M)

Substance index (1)： Rivaroxaban

Reference (26)：

• Mallikarjuna Rao Edupuganti M, Marmagkiolis K, Cilingiroglu M, Uretsky BF, Hakeem A. Optimizing selection of antithrombotic therapy in patients requiring PCI and long term anticoagulation. Cardiovasc Revasc Med. 2014;15:414-420.
• Perez A, Eraso LH, Merli GJ. Implications of new anticoagulants in primary practice. Int J Clin Pract. 2013;67:139-156.
• Thihalolipavan S, Morin DP. Atrial fibrillation and heart failure: update 2015. Prog Cardiovasc Dis. 2015;58:126-135.
• Sandoval Y, Apple FS, Smith SW. High-sensitivity cardiac troponin assays and unstable angina. Eur Heart J Acute Cardiovasc Care 2016 Jul 7.
• Fisch AS, Perry CG, Stephens SH, Horenstein RB, Shuldiner AR. Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep. 2013;15:381.

Terms in the title (4)： 活性化 ,  不活性化 ,  リバロキサバン ,  挙動